Project Title

A study to evaluate the safety and pharmacokinetics of XMAB24306 in combination with daratumumab in participants with relapsed/refractory multiple myeloma.

Official Title

A Phase Ib, open-label, multicenter, dose-escalation study to evaluate the safety and pharmacokinetics of XMAB24306 in combination with daratumumab in patients with relapsed/refractory multiple myeloma.

Project Summary

This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with a multiple myeloma (MM)-targeting monoclonal antibody capable of inducing antibody-dependent cellular toxicity (ADCC) in participants with relapsed or refractory (R/R) MM who have received a minimum of three prior treatments, including at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody.

Blood Disorder

• Relapsed/refractory multiple myeloma

Patient Recruitment Details

Patient recruitment status: commencing soon

Number of patients (Globally)

60